Welcome to our dedicated page for Sage Therapeutic news (Ticker: SAGE), a resource for investors and traders seeking the latest updates and insights on Sage Therapeutic stock.
Sage Therapeutics, Inc. (former Nasdaq: SAGE) is a Cambridge, Massachusetts-based biopharmaceutical company focused on brain health, with a particular emphasis on postpartum depression. The company reports that it developed the only two FDA-approved treatments indicated for postpartum depression and highlights ZURZUVAE (zuranolone), described as the first-and-only oral treatment for adults with postpartum depression and, in some communications, as a once-daily 14-day oral treatment.
The news flow around Sage has centered on several themes. One major area is commercial updates for ZURZUVAE, including collaboration revenue recognized under its agreement with Biogen, prescription shipment trends for women with postpartum depression, prescriber behavior among obstetrician-gynecologists, and payer coverage metrics. Regular quarterly earnings releases have discussed revenue from ZURZUVAE, other collaboration revenue, research and development spending, selling, general and administrative expenses, restructuring charges, and cash runway expectations.
Another recurring topic is Sage’s research and development pipeline. Company news has described progress with SAGE-319, an extrasynaptic-preferring GABAA receptor positive allosteric modulator being studied for behavioral symptoms associated with certain neurodevelopmental disorders, along with preclinical NMDA receptor negative allosteric modulator programs SAGE-817 and SAGE-039, and evaluation of potential indications for SAGE-324, including seizures in developmental and epileptic encephalopathies.
Corporate and strategic developments are also prominent in Sage’s news. Releases have covered a strategic alternatives review, unsolicited acquisition proposals, and, ultimately, the definitive agreement and subsequent completion of an acquisition by Supernus Pharmaceuticals, Inc. Investors reviewing SAGE-related news can use this page to follow historical earnings announcements, pipeline updates, leadership changes, strategic reviews, and the steps that led to Sage becoming a wholly owned subsidiary of Supernus.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.